Strata Skin科学 SSKN 深 沪
已收盘 10-31 16:00:00 美东时间
1.78
-0.050
-2.73%
华盛通- 最 高1.83
- 今 开1.83
- 成交量 18.83万股
- 最 低 1.745
- 昨 收 1.83
- 总市值 937.83万
- 52周最高 3.86
- 市盈率 静 --
- 换手率 3.57%
- 52周最低 1.38
- 委 比 -10.76%
- 总股本 526.87万
- 历史最高 3480.00
- 量 比 0.03
- 振 幅 4.64%
- 历史最低 1.38
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多STRATA Skin Sciences' TheraClearX Treatment For Acne Gets Regulatory Approval From Mexico's Health Authority Through November 2029
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies for the treatment of skin conditions such as acne, psoriasis, and vitiligo, today announced that its TheraClearX®
10-28 20:09
STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements
STRATA Skin Sciences announced that its TheraClearX® acne treatment system has received regulatory clearance from Mexico's COFEPRIS under Device Registration No. 3187E2024SSA, valid through November 2029. This certification is a significant milestone in the company's international expansion strategy, enabling the importation, commercialization, and clinical use of TheraClearX® across Mexico. STRATA has partnered with MINO Labs, a leading Mexican ...
10-28 12:00
STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek
STRATA Skin Sciences secured a court ruling against LaserOptek, restricting sales and marketing of their laser systems for specific CPT codes and barring false claims. The company regained market share by attracting 20 former LaserOptek clients, generating over $1 million in annual revenue. STRATA expects growth with the expansion of CPT codes to cover more skin conditions, enhancing access for patients and revenue for partners. The company remai...
10-20 12:00
Strata Skin Sciences Announces Equity Distribution Agreement
The latest announcement is out from Strata Skin Sciences ( ($SSKN) ). STRATA Sk...
10-17 05:00
STRATA Skin Sciences Publishes Clinical Case Study On 308-Nm Excimer Laser Use In Rare pMF Subtype Of Cutaneous T-Cell Lymphoma
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company's XTRAC capability to
10-14 20:24
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
<p><p>Strata Skin Sciences announced a groundbreaking clinical case study published in <em>Case Reports in Oncology</em>, demonstrating the successful use of 308-nm excimer laser therapy to treat poikilodermatous mycosis fungoides (pMF), a rare subtype of mycosis fungoides (MF). The study, conducted by researchers at Tohoku University, shows rapid clinical resolution of lesions in a patient with pMF, highlighting the safety and efficacy of the XT...
10-14 12:15
Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
STRATA Skin Sciences, Inc. highlights the XTRAC® Excimer Laser as a safe and effective treatment for localized atopic dermatitis, supported by extensive clinical evidence. The American Medical Association has expanded its indications, enabling reimbursement for atopic dermatitis under Medicare, Medicaid, and private insurance. Studies demonstrate significant symptom reduction, improved quality of life, and durability of results. The XTRAC® laser ...
10-03 14:50
Strata Skin's Treatment For Plaque-Type Psoriasis Enhances Outcomes Compared To Topical Monotherapy, Study Demonstrates
HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative
09-30 20:21
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
A study published in Lasers in Medical Science highlights that STRATA Skin Sciences' XTRAC 308nm Excimer Laser, when combined with 0.1% tacrolimus ointment, significantly improves outcomes for plaque-type psoriasis patients compared to topical monotherapy. The randomized study of 100 patients showed a 74% PASI reduction with the combination therapy versus 70% with monotherapy, with no serious adverse events. The findings demonstrate the effective...
09-30 12:15
3 Penny Stocks to Watch Now, 9/25/25
Datavault AI, Strata Skin Sciences, and Soluna Holdings are the 3Penny St...
09-25 23:02
